Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mismetti

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Therapie|July 1, 1994
[Thrombosis and carbamazepine: hazard or causality?]A Dacosta, P Mismetti, B Tardy, et al.
British Journal of Clinical Pharmacology|June 8, 2018
Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysisP J Zufferey, E Ollier, X Delavenne, et al.
Pharmacopsychiatry|July 24, 2012
Antipsychotics: a real or confounding risk factor for venous thromboembolism?C Chapelle, S Quenet, X Delavenne, et al.
Journal of Thrombosis and Haemostasis : JTH|May 11, 2013
Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysisJ-C Lega, P Mismetti, M Cucherat, et al.
Chest|June 23, 1999
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopeniaB Tardy-Poncet, B Tardy, J Reynaud, et al.
American Journal of Hematology|March 1, 1994
Pentosan polysulfate-induced thrombocytopenia and thrombosisB Tardy-Poncet, B Tardy, F Grelac, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Circadian dynamics of coagulation and chronopathology of cardiovascular and cerebrovascular events. Future therapeutic implications for the treatment of these disorders?H Decousus, C Boissier, B Perpoint, et al.
Fundamental & Clinical Pharmacology|March 10, 2009
Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acidX Delavenne, S Laporte, S Demasles, et al.
Revue Des Maladies Respiratoires|April 16, 2021
[Treatment of cancer associated thrombosis. 2019 update of the French guidelines]I Mahé, G Meyer, P Girard, et al.
British Journal of Clinical Pharmacology|May 19, 2007
Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldA Berges, S Laporte, M Epinat, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Therapie|July 1, 1994
[Thrombosis and carbamazepine: hazard or causality?]A Dacosta, P Mismetti, B Tardy, et al.
British Journal of Clinical Pharmacology|June 8, 2018
Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysisP J Zufferey, E Ollier, X Delavenne, et al.
Pharmacopsychiatry|July 24, 2012
Antipsychotics: a real or confounding risk factor for venous thromboembolism?C Chapelle, S Quenet, X Delavenne, et al.
Journal of Thrombosis and Haemostasis : JTH|May 11, 2013
Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysisJ-C Lega, P Mismetti, M Cucherat, et al.
Chest|June 23, 1999
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopeniaB Tardy-Poncet, B Tardy, J Reynaud, et al.
American Journal of Hematology|March 1, 1994
Pentosan polysulfate-induced thrombocytopenia and thrombosisB Tardy-Poncet, B Tardy, F Grelac, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Circadian dynamics of coagulation and chronopathology of cardiovascular and cerebrovascular events. Future therapeutic implications for the treatment of these disorders?H Decousus, C Boissier, B Perpoint, et al.
Fundamental & Clinical Pharmacology|March 10, 2009
Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acidX Delavenne, S Laporte, S Demasles, et al.
Revue Des Maladies Respiratoires|April 16, 2021
[Treatment of cancer associated thrombosis. 2019 update of the French guidelines]I Mahé, G Meyer, P Girard, et al.
British Journal of Clinical Pharmacology|May 19, 2007
Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldA Berges, S Laporte, M Epinat, et al.
Pageof 11